Genetically proxied inhibition of L-2-hydroxyglutarate

dehydrogenase and the risk of coronary artery disease: A

Mendelian randomization study

Euijun Song, M.D.

Yonsei University College of Medicine, Seoul, Republic of Korea

Correspondence: drjunsong@gmail.com (Euijun Song)

Conflicts of interest: All authors have no financial conflicts of interest to declare.

Abstract

Background: L-2-hydroxyglutarate dehydrogenase (L2HGDH) deletion-induced L-2-hydroxyglutarate accumulation plays a cardioprotective role in hypoxic conditions. However, there has been no causal evidence in real-world clinical data. We aimed to examine the causal effects of *L2HGDH* inhibition on coronary artery disease (CAD) and myocardial infarction (MI) using Mendelian randomization (MR) analysis.

Methods: We used nine *L2HGDH*-proxied genetic variants associated with blood 2-hydroxyglutarate levels as genetic instruments, and performed two-sample MR analysis using the CARDIoGRAMplusC4D meta-analysis datasets of CAD (60,801 CAD cases and 123,504 controls) and MI (34,541 MI cases and 261,984 controls).

Results: Genetically proxied inhibition of *L2HGDH* associated with 2-hydroxyglutarate levels potentially decreased the risk of CAD (odds ratio [OR] 0.486, 95% confidence interval [CI] 0.242–0.977, P=0.043) but was not associated with the risk of MI (OR 0.676, 95% CI 0.312–1.463, P=0.320). This potentially causal association between *L2HGDH* inhibition and CAD was unlikely to be biased by horizontal pleiotropy, whereas there might be a weak instrument bias.

Conclusion: Our MR analysis suggests the potential association between genetically proxied inhibition of *L2HGDH* and CAD. Our findings may have therapeutic implications for L2HGDH inhibitors in CAD, and further large-scale clinical studies are needed.

Keywords: L-2-hydroxyglutarate dehydrogenase; coronary artery disease; therapeutics; Mendelian randomization; metabolism

1. Introduction

L-2-hydroxyglutarate plays a pivotal role in cytoplasmic and mitochondrial energy metabolism to maintain redox regulation [1]. Hypoxia increases cellular L-2-hydroxyglutarate, which is produced from α-ketoglutarate by malate dehydrogenase [1-3]. L-2-hydroxyglutarate dehydrogenase (L2HGDH) is the only enzyme known to oxidize L-2-hydroxyglutarate back to α-ketoglutarate [2, 4]. In experiments, *L2HGDH* ablation increases the accumulation of L-2-hydroxyglutarate in hypoxia [2, 5]. L-2-hydroxyglutarate has been known to protect heart tissue from oxidative stress in response to hypoxia [5]. Since coronary artery disease (CAD) leads to ischemic injury and ischemia-reperfusion injury, L-2-hydroxyglutarate may play a protective role in CAD and ischemic myocardial injury.

Metabolic remodeling plays a key role in the pathobiology of CAD and myocardial infarction (MI) [5-7]. Recently, He and colleagues [5] discovered that genetic *L2HGDH* deletion-induced L-2-hydroxyglutarate accumulation shows cardioprotective effects under ischemic conditions in mice. They found that L-2-hydroxyglutarate accumulation shifts glucose metabolisms from glycolysis to the pentose phosphate pathway in response to low-flow ischemia or ischemia-reperfusion. This metabolic shift indicates that *L2HGDH* deletion-induced L-2-hydroxyglutarate accumulation could reduce ischemic myocardial damage by eliminating reactive oxygen species. The experiments suggest that *L2HGDH* is a potential therapeutic target for oxidative stress-related cardiovascular diseases, such as CAD and MI. However, there has been no prospective clinical trial yet.

One genetic epidemiological approach for testing the causal effects of drug targets on

complex diseases is the Mendelian randomization (MR) method [8-12]. MR methods

can estimate the causal effects of putative risk factors based on germline genetic

variation in the population, without conducting a randomized controlled trial. Using the

drug-target MR framework, Ference and colleagues [8] determined the causal

associations of ATP citrate lyase (ACLY) and HMG-CoA reductase (HMGCR) inhibitions

with the risk of cardiovascular disease. Similarly, MR approaches could identify the

potentially causal associations of genetically proxied inhibition of cardiovascular drug

targets with cancers, neuropsychiatric diseases, and cognitive function [9-12].

Here, we conduct a two-sample MR study to assess putative causal effects of

genetically proxied inhibition of *L2HGDH* on CAD and MI (Figure 1). We construct

genetic instruments for *L2HGDH* that are associated with blood 2-hydroxyglutarate

levels. We then perform MR analysis to test whether this genetic instrument is causally

associated with CAD and MI using large-scale genome-wide association study (GWAS)

datasets.

2. Methods

2.1. Mendelian randomization study design

As illustrated in Figure 1, we designed a two-sample MR study to determine putative

causal effects of genetically proxied inhibition of *L2HGDH* on CAD and MI. We first

constructed the genetic instruments for *L2HGDH* to mimic pharmacological/genetic

perturbation of *L2HGDH* for increasing L-2-hydroxyglutarate levels. Due to the limited

availability of GWAS data for L-2-hydroxyglutarate levels, we constructed the genetic

instruments that are associated with 2-hydroxyglutarate level instead. We then

performed the Mendelian randomization analysis to determine potential causal

associations between the genetic instruments for *L2HGDH* and CAD using large-scale

GWAS summary statistics datasets.

2.2. Genetic instruments for genetically proxied inhibition of *L2HGDH*

We obtained the GWAS summary statistics for human blood metabolome from Shin et

al [13]. Shin et al. [13] analyzed >400 blood metabolites from the KORA and TwinsUK

European population datasets using the Metabolon platform. Since the Metabolon

platform could not distinguish L-2-hydroxyglutarate from D-2-hydroxyglutarate, we

alternatively used the GWAS data for 2-hydroxyglutarate levels (accessed from

https://gwas.mrcieu.ac.uk/) to construct the genetic instruments for *L2HGDH*.

L2HGDH is the only enzyme known to catabolize L-2-hydroxyglutarate in human cells,

and L2HGDH inhibition increases L-2-hydroxyglutarate levels in experiments [1, 2].

Since 2-hydroxyglutarate includes both L-2-hydroxyglutarate and D-2-hydroxyglutarate,

we only considered *L2HGDH*-proxied genetic variants to mainly reflect L-2-

hydroxyglutarate levels. We constructed the genetic instruments for *L2HGDH* by

recruiting genetic variants within ± 500 kb from the *L2HGDH* gene that are associated

with blood 2-hydroxyglutarate level (P<0.05) and that are also in low linkage

disequilibrium (r^2<0.3, with the default clumping window size of 10000 kb) [8]. The

characteristics of genetic variants proxied to *L2HGDH* are shown in Table S1. Since

there was no genome-wide significant variant near the *L2HGDH* gene (Table S2), we

adopted weak P-value and r^2 thresholds previously suggested by Ference and

colleagues [8]. The SNPs and *L2HGDH* gene were analyzed based on the GRCh37

(hg19) human genome reference (Figure S1). The PhenoScanner V2

(http://www.phenoscanner.medschl.cam.ac.uk/, accessed on Feb 6, 2023) was used to

identify pleiotropic variants (Table S3).

2.3. Data sources for CAD and MI

The GWAS summary statistics for CAD was obtained from the CARDIoGRAMplusC4D

(Coronary Artery DIsease Genome-wide Replication and Meta-analysis plus Coronary

Artery Disease) 1000 Genomes-based GWAS meta-analysis study

(http://www.cardiogramplusc4d.org) [14]. The CARDIoGRAMplusC4D GWAS meta-

analysis dataset included genetic associations from 60,801 CAD cases and 123,504

controls mostly of European ancestry. The case status was defined by diagnosis of

CAD, including MI, acute coronary syndrome, chronic stable angina, and coronary

stenosis >50% [14]. In addition, the MI GWAS summary statistics was obtained from the

same CARDIoGRAMplusC4D meta-analysis study (34,541 MI cases and 261,984

controls). All the MI cases are a subpopulation of the CAD cases [14].

2.4. Mendelian randomization and statistical analysis

For MR analysis, the instrument strength was measured using the F-statistic. The F-

statistic less than 10 indicates weak instruments. We used the inverse-variance

weighted (IVW), weighted median, maximum likelihood, MR-PRESSO [15], Radial-MR

[16], and MR-RAPS [17] methods to evaluate the putative causal effects of genetically

proxied inhibition of *L2HGDH* on CAD and MI. The heterogeneity between SNPs was

evaluated by Cochran's Q test [18]. We also performed the MR Steiger directionality

test to determine the directionality of causality [19]. To assess potential directional and

horizontal pleiotropy, we used the MR-Egger intercept test and MR-PRESSO methods.

The leave-one-out sensitivity analysis and Radial-MR were used to detect potential

outlying genetic variants. $P<0.05$ was considered statistically significant. All MR

analyses were performed in R (version 4.1.2, https://www.r-project.org/) with the

packages TwoSampleMR, MRPRESSO, and RadialMR.

3. Results

3.1. Genetic instruments for *L2HGDH*

We first constructed the genetic instruments proxied to *L2HGDH* that are associated

with blood 2-hydroxyglutarate levels ($P<0.05$) and that are also in low linkage

disequilibrium ($r^2<0.3$; Table S1). Since there was no genome-wide significant variant

associated with 2-hydroxyglutarate levels near the *L2HGDH* gene (Table S2), we

adopted a loose significance threshold of 0.05 to construct instruments for genetically

proxied inhibition of *L2HGDH* [8]. These genetic instruments mimic genetic or

pharmacological inhibition of *L2HGDH* for increasing blood 2-hydroxyglutarate levels

(Figure 1). The genetic instruments have the mean F-statistic of 7.661, indicating that

there might be a weak instrument bias in our MR analysis. The genetic instruments are

not associated with possible confounders or cardiovascular diseases/traits (Table S3).

3.2. Association of genetically proxied inhibition of *L2HGDH* with CAD and MI

We performed a two-sample MR analysis using the CARDIoGRAMplusC4D GWAS

meta-analysis dataset of CAD (60,801 CAD cases and 123,504 controls). As highlighted

in Table 1, the IVW method showed that genetically proxied inhibition of *L2HGDH*

associated with 2-hydroxyglutarate levels potentially decreased the risk of CAD (OR

0.486, 95% CI 0.242–0.977, P=0.043). There was no significant evidence of

heterogeneity (Cochran's Q-statistic=5.757, P=0.674). The radial IVW, weighted

median, and maximum likelihood methods also showed directionally similar estimates

(Table 1). The MR-RAPS method indicated that there might be a slightly weak

instrument bias (OR 0.460, 95% CI 0.202–1.046, P=0.064). The MR Steiger

directionality test confirmed the direction of the causality (P<0.001).

To assess potential directional horizontal pleiotropy, we used the MR-Egger and MR-

PRESSO methods. The MR-Egger intercept test determined that 9 genetic variants for

L2HGDH showed no evidence for significant pleiotropy (intercept=-0.014, P=0.396).

The MR-PRESSO global test also confirmed no significant horizontal pleiotropy with no

outlying genetic variants (P=0.715). In addition, the leave-one-out sensitivity analysis

showed that removing individual genetic variants did not substantially change the

estimated causal effect of genetically proxied inhibition of *L2HGDH* (Table S4). The

radial IVW method further confirmed no evidence of outlying genetic variants (Figure

S2). Taken together, the sensitivity analyses provide no significant evidence for

pleiotropic effects, which could bias the MR analysis.

As a subpopulation of the CAD cases, we also examined the putative causal

association between *L2HGDH* inhibition and MI using the CARDIoGRAMplusC4D meta-

analysis dataset of MI (34,541 MI cases and 261,984 controls). Using IVW, we found

that genetically proxied inhibition of *L2HGDH* was not significantly associated with the

risk of MI (OR 0.676, 95% CI 0.312–1.463, P=0.320). The MR-Egger intercept and MR-

PRESSO global tests indicated no significant pleiotropy (Table 1), and the radial plot

indicated no evidence of outlying variants (Figure S2).

4. Discussion

To our knowledge, this is the first MR study to demonstrate the potentially causal

association between genetically proxied inhibition of *L2HGDH* and CAD. Using two-

sample MR analyses, we revealed that genetically proxied inhibition of *L2HGDH* was

significantly associated with the decreased risk of CAD. The multiple MR sensitivity

analyses confirmed that this potential causal association was unlikely to be biased by

horizontal pleiotropy. Our findings suggests that genetic/pharmacological targeting of

L2HGDH may decrease the risk of CAD by increasing blood 2-hydroxyglutarate levels.

Since our genetic instruments are not directly associated with L-2-hydroxyglutarate

levels and there might be a weak instrument bias, further large-scale GWAS studies are

needed to obtain more robust and reliable MR results.

In the previous experimental study, *L2HGDH* deletion-induced L-2-hydroxyglutarate

accumulation protects the heart from redox stress, which plays a key role in myocardial

ischemic injury [5]. However, there has been no clinical trial to validate this potential

cardioprotective effect of *L2HGDH* inhibition. Using large-scale MR, we revealed that

genetically proxied inhibition of *L2HGDH* could potentially decrease the risk of CAD but

was not significantly associated with MI *per se* (Table 1). In our MR study, the CAD

cases include MI, acute coronary syndrome, coronary atherosclerosis, and chronic

ischemic heart diseases. Therefore, our findings suggest that *L2HGDH* inhibition may

play a cardioprotective role in not only being limited to myocardial ischemic damage, but

also in the primary prevention of CAD. The mechanisms underlying the potential

preventive effects of *L2HGDH* inhibition on CAD should be further investigated.

Due to the limited availability of GWAS data on blood metabolome, we constructed

genetic instruments based on blood 2-hydroxyglutarate levels, including its two

enantiomers L-2-hydroxyglutarate and D-2-hydroxyglutarate. D-2-hydroxyglutarate has

been known to be an oncometabolite in certain types of rare cancers [20, 21]. To

minimize the effects of D-2-hydroxyglutarate in our MR analysis, we constructed the

genetic instruments only proxied to the *L2HGDH* gene. In experiments, L-2-

hydroxyglutarate is the majority of 2-hydroxyglutarate, and *L2HGDH* but not D2HGDH

knockdown increases the concentration of 2-hydroxyglutarate [1, 2]. Additionally,

L2HGDH is the only reported enzyme that metabolizes L-2-hydroxyglutarate. Therefore,

our approach would mainly reflect *L2HGDH* inhibition-related L-2-hydroxyglutarate

levels; however, large-scale GWAS data of blood L-2-hydroxyglutarate levels is

essential to obtain more robust and reliable MR results. Since L-2-hydroxyglutarate is

also a putative oncometabolite in renal cell carcinoma [22, 23], further

epidemiological/clinical studies are warranted to determine the potential side effects of

L2HGDH inhibition.

A critical limitation of this study is that we adopted a loose P-value threshold of 0.05 to

build the genetic instruments [8]. When we used the genome-wide significance

threshold, there was no genetic variant associated with blood 2-hydroxyglutarate levels,

near the *L2HGDH* gene (Table S2). Since L2HGDH is the only enzyme known to

metabolize L-2-hydroxyglutarate, we only considered *L2HGDH*-proxied variants to

reflect the physiological effects of *L2HGDH* inhibition on L-2-hydroxyglutarate levels [1,

2]. In addition, we did not perform any replication analysis in non-European populations,

though the CARDIoGRAMplusC4D is the largest consortium study of CAD. Another

critical limitation is the underlying overlap between exposure and outcome datasets, as

the CARDIoGRAMplusC4D includes KORA (also known as GerMIFS III) and TwinsUK

(part of the PROCARDIS) datasets. This overlap could cause a bias towards

confounded associations in the two-sample MR [24]. In our MR analysis, the weighted

median methods did not show significant results; however, those methods are

statistically less powerful than IVW [25]. Large-scale multi-ancestry GWAS datasets for

L-2-hydroxyglutarate are essential to construct more robust genetic instruments.

Protein-protein interaction network analysis would be helpful to determine the functional

relationship between L2HGDH and the CAD disease module and to identify potential

drug targets [26, 27].

5. Conclusion

247 Our MR result suggests the potential association between genetically proxied inhibition

248 of *L2HGDH* and CAD, though there might be a weak instrument bias. Our findings may

249 have therapeutic implications for L2HGDH inhibitors in CAD. Further large-scale clinical

250 studies are needed to obtain more robust results.

Authorship contribution

254 Euijun Song designed, performed, analyzed data, and wrote the manuscript.

Acknowledgements

258 This research received no external funding. This study only used publicly available

259 GWAS summary statistics datasets. The author would like to thank Drs. Loscalzo and

260 Cheng for insightful discussions and comments.

References

1. Oldham, W.M., et al., *Hypoxia-Mediated Increases in L-2-hydroxyglutarate Coordinate the Metabolic Response to Reductive Stress.* Cell Metab, 2015. **22**(2): p. 291-303.

2. Intlekofer, A.M., et al., *Hypoxia Induces Production of L-2-Hydroxyglutarate.* Cell Metab, 2015. **22**(2): p. 304-11.

3. Chakraborty, A.A., et al., *Histone demethylase KDM6A directly senses oxygen to control chromatin and cell fate.* Science, 2019. **363**(6432): p. 1217-1222.

4. Rzem, R., et al., *A gene encoding a putative FAD-dependent L-2-hydroxyglutarate dehydrogenase is mutated in L-2-hydroxyglutaric aciduria.* Proc Natl Acad Sci U S A, 2004. **101**(48): p. 16849-54.

5. He, H., et al., *L-2-Hydroxyglutarate Protects Against Cardiac Injury via Metabolic Remodeling.* Circ Res, 2022. **131**(7): p. 562-579.

6. Xiao, W., et al., *Immunometabolic Endothelial Phenotypes: Integrating Inflammation and Glucose Metabolism.* Circ Res, 2021. **129**(1): p. 9-29.

7. Lee, L.Y., et al., *Interferon-gamma Impairs Human Coronary Artery Endothelial Glucose Metabolism by Tryptophan Catabolism and Activates Fatty Acid Oxidation.* Circulation, 2021. **144**(20): p. 1612-1628.

8. Ference, B.A., et al., *Mendelian Randomization Study of ACLY and Cardiovascular Disease.* N Engl J Med, 2019. **380**(11): p. 1033-1042.

9. Yarmolinsky, J., et al., *Genetically proxied therapeutic inhibition of antihypertensive drug targets and risk of common cancers: A mendelian randomization analysis.* PLoS Med, 2022. **19**(2): p. e1003897.

10. Sun, L., et al., *Associations of genetically proxied inhibition of HMG-CoA reductase, NPC1L1, and PCSK9 with breast cancer and prostate cancer.* Breast Cancer Res, 2022. **24**(1): p. 12.

11. Rosoff, D.B., et al., *Mendelian Randomization Study of PCSK9 and HMG-CoA Reductase Inhibition and Cognitive Function.* J Am Coll Cardiol, 2022. **80**(7): p. 653-662.

12. Bell, A.S., et al., *Comparing the Relationships of Genetically Proxied PCSK9 Inhibition With Mood Disorders, Cognition, and Dementia Between Men and*

293   *Women: A Drug-Target Mendelian Randomization Study.* J Am Heart Assoc,

294   2022. **0**(0): p. e026122.

295 13. Shin, S.Y., et al., *An atlas of genetic influences on human blood metabolites.* Nat

296   Genet, 2014. **46**(6): p. 543-550.

297 14. Nikpay, M., et al., *A comprehensive 1,000 Genomes-based genome-wide*

298   *association meta-analysis of coronary artery disease.* Nat Genet, 2015. **47**(10):

299   p. 1121-1130.

300 15. Verbanck, M., et al., *Detection of widespread horizontal pleiotropy in causal*

301   *relationships inferred from Mendelian randomization between complex traits and*

302   *diseases.* Nat Genet, 2018. **50**(5): p. 693-698.

303 16. Bowden, J., et al., *Improving the visualization, interpretation and analysis of two-*

304   *sample summary data Mendelian randomization via the Radial plot and Radial*

305   *regression.* Int J Epidemiol, 2018. **47**(4): p. 1264-1278.

306 17. Zhao, Q., et al., *Statistical inference in two-sample summary-data Mendelian*

307   *randomization using robust adjusted profile score.* The Annals of Statistics, 2020.

308   **48**(3): p. 1742-1769.

309 18. Burgess, S., et al., *Sensitivity Analyses for Robust Causal Inference from*

310   *Mendelian Randomization Analyses with Multiple Genetic Variants.*

311   Epidemiology, 2017. **28**(1): p. 30-42.

312 19. Hemani, G., K. Tilling, and G. Davey Smith, *Orienting the causal relationship*

313   *between imprecisely measured traits using GWAS summary data.* PLoS Genet,

314   2017. **13**(11): p. e1007081.

315 20. Rakheja, D., et al., *The emerging role of d-2-hydroxyglutarate as an*

316   *oncometabolite in hematolymphoid and central nervous system neoplasms.* Front

317   Oncol, 2013. **3**: p. 169.

318 21. Jezek, P., *2-Hydroxyglutarate in Cancer Cells.* Antioxid Redox Signal, 2020.

319   **33**(13): p. 903-926.

320 22. Shelar, S., et al., *Biochemical and Epigenetic Insights into L-2-Hydroxyglutarate,*

321   *a Potential Therapeutic Target in Renal Cancer.* Clin Cancer Res, 2018. **24**(24):

322   p. 6433-6446.

323   23.   Shim, E.H., et al., *L-2-Hydroxyglutarate: an epigenetic modifier and putative*

324   *oncometabolite in renal cancer.* Cancer Discov, 2014. **4**(11): p. 1290-8.

325   24.   Burgess, S., N.M. Davies, and S.G. Thompson, *Bias due to participant overlap in*

326   *two-sample Mendelian randomization.* Genet Epidemiol, 2016. **40**(7): p. 597-608.

327   25.   Bowden, J., *Misconceptions on the use of MR-Egger regression and the*

328   *evaluation of the InSIDE assumption.* Int J Epidemiol, 2017. **46**(6): p. 2097-2099.

329   26.   Cheng, F., et al., *Network-based approach to prediction and population-based*

330   *validation of in silico drug repurposing.* Nat Commun, 2018. **9**(1): p. 2691.

331   27.   Lee, L.Y., et al., *Network medicine in Cardiovascular Research.* Cardiovasc Res,

332   2021. **117**(10): p. 2186-2202.

Figure 1. Overall analysis scheme. (A) Function of L-2-hydroxyglutarate

dehydrogenase (L2HGDH) in energy metabolisms. Inhibition of L2HGDH increases

blood L-2-hydroxyglutarate levels. (B) We constructed genetic instruments proxied to

the *L2HGDH* gene that are associated with blood 2-hydroxyglutarate levels. We then

performed two-sample Mendelian randomization analysis to assess the causal effects of

genetically proxied inhibition of *L2HGDH* on coronary artery disease and myocardial

infarction.

343　**Table 1.** Mendelian randomization (MR) analyses for causal associations of genetically proxied inhibition of *L2HGDH* with

344　coronary artery disease and myocardial infarction.

	Coronary artery disease (60,801 cases, 123,504 controls)			Myocardial infarction (34,541 cases, 261,984 controls)		
	OR (95% CI)	**P-value**	**SNPs**	**OR (95% CI)**	**P-value**	**SNPs**
IVW	0.486 (0.242–0.977)	0.043	9	0.676 (0.312–1.463)	0.320	9
IVW (Radial)	0.487 (0.269–0.880)	0.017	9	0.676 (0.361–1.268)	0.222	9
Weighted median	0.762 (0.300–1.937)	0.568	9	0.888 (0.325–2.428)	0.817	9
Maximum likelihood	0.457 (0.216–0.967)	0.041	9	0.655 (0.291–1.476)	0.308	9
MR-RAPS	0.460 (0.202–1.046)	0.064	9	0.681 (0.284–1.630)	0.388	9
MR-Egger intercept*	-0.014 (0.016)	0.396	9	-0.004 (0.017)	0.836	9
MR-PRESSO global[#]	-	0.715	9	-	0.752	9
MR Steiger directionality	-	<0.001	9	-	<0.001	9

SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval; IVW, inverse-variance weighted method.

*Intercept values are presented with SE.

[#]No outlying genetic variants were detected.

Supplementary materials

Figure S1. Genomic positions of nine genetic instruments for genetically proxied

inhibition of *L2HGDH*. The genomic positions were visualized using the NCBI Graphical

Sequence Viewer (GRCh37, accessed on Oct 29, 2022).

Figure S2. Radial inverse-variance weighted (IVW) Mendelian randomization plots for

coronary artery disease (A) and myocardial infarction (B). Black dots indicate valid

genetic variants. The estimated effect sizes are presented. There is no outlier variant in

the present radial plots.

Table S1. Nine *L2HGDH*-proxied (± 500 kb) genetic variants that are associated with

blood 2-hydroxyglutarate levels ($P<0.05$, $r^2<0.3$).

SNP	Position (GRCh37)	EA/OA	EAF	β (SE)*	P-value	F-statistic
rs11628742	chr14:50515075	C/T	0.438	-0.0112 (0.0043)	9.02×10^{-3}	6.784
rs11625406	chr14:50516192	A/C	0.619	0.0070 (0.0033)	3.56×10^{-2}	4.500
rs8017367	chr14:50675487	T/C	0.261	-0.0121 (0.0034)	4.00×10^{-4}	12.665
rs12894758	chr14:50760030	T/C	0.291	0.0135 (0.0034)	6.80×10^{-5}	15.766
rs9323183	chr14:50796881	C/G	0.054	-0.0150 (0.0071)	3.37×10^{-2}	4.463
rs11570815	chr14:50825258	T/A	0.662	0.0094 (0.0033)	4.88×10^{-3}	8.114
rs17791680	chr14:50965445	A/G	0.372	-0.0081 (0.0034)	1.64×10^{-2}	5.676
rs2144975	chr14:50969448	C/T	0.955	0.0170 (0.0075)	2.44×10^{-2}	5.138
rs2012893	chr14:51073443	G/A	0.088	-0.0145 (0.0060)	1.53×10^{-2}	5.840

363 SNP, single nucleotide polymorphism; EA, effect allele; OA, other allele; EAF, effective

364 allele frequency.

365 *Log(odds ratio) per 1-SD increase in blood 2-hydroxyglutarate levels.

367 **Table S2.** Genetic variants associated with blood 2-hydroxyglutarate levels ($P<1\times10^{-5}$,

368 $r^2<0.3$).

SNP	Position (GRCh37)	EA/OA	EAF	β (SE)*	P-value
rs10196007	chr2:145329033	C/T	0.184	0.0320 (0.0065)	7.63×10^{-7}
rs1568101	chr3:148590090	T/C	0.912	-0.0255 (0.0057)	8.62×10^{-6}
rs7725624	chr5:63010725	A/C	0.087	-0.0440 (0.0094)	3.02×10^{-6}
rs7702827	chr5:158879869	G/C	0.700	0.0152 (0.0034)	6.29×10^{-6}
rs933341	chr7:83743619	G/A	0.760	-0.0166 (0.0035)	1.56×10^{-6}
rs8176023	chr7:142642596	G/A	0.072	0.0411 (0.0087)	2.46×10^{-6}
rs890519	chr8:18905049	A/C	0.416	0.0147 (0.0033)	9.06×10^{-6}
rs10966201	chr9:24079188	C/T	0.345	-0.0151 (0.0034)	7.11×10^{-6}
rs11793331	chr9:133298199	T/C	0.024	0.0619 (0.0136)	5.09×10^{-6}
rs6484669	chr11:11120287	C/T	0.259	0.0196 (0.0044)	7.75×10^{-6}
rs9544785	chr13:78971070	A/C	0.361	-0.0150 (0.0033)	6.63×10^{-6}
rs16977497	chr17:71021645	A/G	0.045	0.0538 (0.0122)	9.91×10^{-6}
rs6064820	chr20:58206004	T/C	0.723	0.0155 (0.0034)	4.01×10^{-6}

369 SNP, single nucleotide polymorphism; EA, effect allele; OA, other allele; EAF, effective

370 allele frequency.

371 *Log(odds ratio) per 1-SD increase in blood 2-hydroxyglutarate levels.

373 **Table S3.** Phenotypes associated with the *L2HGDH*-proxied genetic instruments based

374 on PhenoScanner V2 (accessed on Feb 6, 2023).

SNP	Associated phenotypes (P<1×10^{-5})
rs11628742	-
rs11625406	-
rs8017367	-
rs12894758	Impedance of arm right; Impedance of arm left
rs9323183	-
rs11570815	-
rs17791680	Impedance of arm right; Impedance of arm left; Sitting height; Arm fat-free mass right
rs2144975	Treatment with inderal 10mg tablet
rs2012893	-

376 **Table S4.** Leave-one-out sensitivity analyses for the causal associations of genetically

377 proxied *L2HGDH* inhibition with coronary artery disease and myocardial infarction using

378 the inverse-variance weighted method.

Removed SNP	Coronary artery disease		Myocardial infarction	
	OR (95% CI)	P-value	OR (95% CI)	P-value
rs2144975	0.576 (0.277–1.194)	0.138	0.826 (0.369–1.847)	0.641
rs11570815	0.545 (0.259–1.150)	0.111	0.770 (0.337–1.758)	0.535
rs11625406	0.535 (0.260–1.103)	0.090	0.715 (0.321–1.590)	0.410
rs17791680	0.499 (0.240–1.036)	0.062	0.668 (0.297–1.499)	0.328
rs9323183	0.461 (0.225–0.945)	0.035	0.644 (0.291–1.425)	0.278
rs2012893	0.457 (0.222–0.941)	0.034	0.657 (0.296–1.461)	0.304
rs8017367	0.455 (0.212–0.979)	0.044	0.553 (0.237–1.289)	0.170
rs11628742	0.445 (0.209–0.947)	0.036	0.625 (0.271–1.442)	0.270
rs12894758	0.411 (0.188–0.899)	0.026	0.648 (0.272–1.542)	0.326
None (original)	0.486 (0.242–0.977)	0.043	0.676 (0.312–1.463)	0.320

379 SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval.